Literature DB >> 19812442

Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.

Alex J Thompson1, Danni Colledge, Sally Rodgers, Rachel Wilson, Peter Revill, Paul Desmond, Ashley Mansell, Kumar Visvanathan, Stephen Locarnini.   

Abstract

BACKGROUND: Toll-like receptors (TLRs) are a key component of the innate immune system and TLR2 has been shown to be involved in the immunopathogenesis of hepatitis B virus (HBV) infection in vivo. We investigated the role of TLR2 stimulation of virus-infected hepatocyte cell lines as a potential antiviral mechanism in vitro.
METHODS: The hepatoblastoma cell line HepG2 was transduced with recombinant HBV baculoviruses and the hepatoma cell line Huh-7 was transiently transfected with complimentary DNA clones of HBV. HBV viral replication was quantified after stimulation with interleukin (IL)-1beta and Pam-2-Cys, a synthetic TLR2 ligand, by measuring intracellular core-associated single-stranded HBV DNA using Southern blot hybridization, as well as viral nucleocapsid formation using a non-denaturing immunoblot method.
RESULTS: Stimulation of both cell lines in vitro with IL-1beta and Pam-2-Cys, both known to induce expression of the pro inflammatory cytokines tumour necrosis factor-alpha and IL-8 via a nuclear factor-kappaB dependent pathway, resulted in the inhibition of HBV DNA replication in the transduced HepG2 cells by up to 90% and nucleocapsid formation in the transiently transfected Huh-7 cells by up to 30%, when compared with mock-treated cells.
CONCLUSIONS: Hepatoma cell lines expressed functional IL-1 receptor and TLR2 receptors, which when stimulated led to a signalling cascade that inhibited HBV replication. These data support an active role for hepatocytes in inhibiting HBV replication and provide a rationale for the development of TLR agonists as potentially novel antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812442     DOI: 10.3851/IMP1294

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  24 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 2.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 3.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

Review 4.  Hepatitis B virus resistance to antiviral drugs: where are we going?

Authors:  Fabien Zoulim
Journal:  Liver Int       Date:  2011-01       Impact factor: 5.828

5.  Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.

Authors:  Catherine Isabell Real; Melanie Werner; Andreas Paul; Guido Gerken; Joerg Friedrich Schlaak; Andrew Vaillant; Ruth Broering
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

Review 6.  Overview of hepatitis B viral replication and genetic variability.

Authors:  Shuping Tong; Peter Revill
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

Review 7.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Masato Nakamura; Tatsuo Miyamura; Shingo Nakamoto; Arup Banerjee; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma.

Authors:  Wenna Shi; Lihui Su; Qianqian Li; Lidan Sun; Jing Lv; Jun Li; Baoquan Cheng
Journal:  Tumour Biol       Date:  2014-06-27

10.  Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

Authors:  S Jegaskanda; S H Ahn; N Skinner; A J Thompson; T Ngyuen; J Holmes; R De Rose; M Navis; W R Winnall; M Kramski; G Bernardi; J Bayliss; D Colledge; V Sozzi; K Visvanathan; S A Locarnini; S J Kent; P A Revill
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.